MX2020008523A - Compuesto que tiene actividad agonista del receptor esfingosina-1-fosfato [(2s,3r,4e)-2-amino-3-hidroxioctadec-4-enil- 1-fosfato (s1p5). - Google Patents
Compuesto que tiene actividad agonista del receptor esfingosina-1-fosfato [(2s,3r,4e)-2-amino-3-hidroxioctadec-4-enil- 1-fosfato (s1p5).Info
- Publication number
- MX2020008523A MX2020008523A MX2020008523A MX2020008523A MX2020008523A MX 2020008523 A MX2020008523 A MX 2020008523A MX 2020008523 A MX2020008523 A MX 2020008523A MX 2020008523 A MX2020008523 A MX 2020008523A MX 2020008523 A MX2020008523 A MX 2020008523A
- Authority
- MX
- Mexico
- Prior art keywords
- agonist activity
- receptor
- compound
- receptor agonist
- binswanger
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
- C07C49/24—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups
- C07C49/252—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing hydroxy groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/527—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings
- C07C49/577—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se proporciona un compuesto en el que el equilibrio de la actividad agonista contra el receptor S1P5 con respecto al receptor S1P1 ha sido mejorado para desarrollar un producto farmacéutico útil para el tratamiento de las enfermedades mediadas por S1P5, tales como la esquizofrenia y la enfermedad de Binswanger y otras enfermedades neurodegenerativas. Este compuesto representado por la fórmula general (V) (en la fórmula, todos los símbolos son como se definieron en la descripción) tiene un equilibrio mejorado de la actividad agonista contra el receptor S1P5 con respecto al receptor S1P1, y por consiguiente puede servir como un agente terapéutico para las enfermedades mediadas por S1P5, tales como la esquizofrenia y la enfermedad de Binswanger y otras enfermedades neurodegenerativas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018029549 | 2018-02-22 | ||
| PCT/JP2019/006637 WO2019163917A1 (ja) | 2018-02-22 | 2019-02-21 | Ｓ１ｐ５受容体作動活性を有する化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020008523A true MX2020008523A (es) | 2020-09-18 |
Family
ID=67688486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008523A MX2020008523A (es) | 2018-02-22 | 2019-02-21 | Compuesto que tiene actividad agonista del receptor esfingosina-1-fosfato [(2s,3r,4e)-2-amino-3-hidroxioctadec-4-enil- 1-fosfato (s1p5). |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11198672B2 (es) |
| EP (2) | EP3757091B9 (es) |
| JP (2) | JP7211410B2 (es) |
| KR (1) | KR102823671B1 (es) |
| CN (1) | CN111757869B (es) |
| AU (1) | AU2019224344B2 (es) |
| CA (1) | CA3091216A1 (es) |
| DK (1) | DK3757091T5 (es) |
| ES (1) | ES2993172T3 (es) |
| FI (1) | FI3757091T3 (es) |
| HU (1) | HUE068382T2 (es) |
| IL (1) | IL276656B1 (es) |
| MX (1) | MX2020008523A (es) |
| MY (1) | MY210277A (es) |
| PH (1) | PH12020551297A1 (es) |
| PL (1) | PL3757091T3 (es) |
| PT (1) | PT3757091T (es) |
| SG (1) | SG11202007896YA (es) |
| TW (2) | TWI789495B (es) |
| WO (1) | WO2019163917A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI789495B (zh) | 2018-02-22 | 2023-01-11 | 日商小野藥品工業股份有限公司 | 具有ｓ1ｐ5受體作動活性的化合物 |
| EP4019496B1 (en) * | 2019-08-20 | 2024-06-05 | ONO Pharmaceutical Co., Ltd. | Salt and crystal form of compound having agonistic activity to s1p5 receptor |
| WO2024006985A1 (en) * | 2022-07-01 | 2024-01-04 | Autobahn Therapeutics, Inc. | Amide prodrugs and uses thereof |
| WO2025119254A1 (en) | 2023-12-06 | 2025-06-12 | Ono Pharmaceutical Co., Ltd. | Method for preparing dihydronaphthalene derivative |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005020882A (ja) | 2003-06-25 | 2005-01-20 | Matsushita Electric Works Ltd | モータアクチュエータ装置 |
| US7825109B2 (en) | 2003-08-29 | 2010-11-02 | Ono Pharmaceutical Co., Ltd. | Compound capable of binding S1P receptor and pharmaceutical use thereof |
| AU2004268455B2 (en) | 2003-08-29 | 2009-12-17 | Ono Pharmaceutical Co., Ltd. | Compound capable of binding S1P receptor and pharmaceutical use thereof |
| EP1765379A4 (en) | 2004-06-17 | 2009-05-27 | Transform Pharmaceuticals Inc | PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS AND RELEVANT USE METHOD |
| WO2006001463A1 (ja) * | 2004-06-23 | 2006-01-05 | Ono Pharmaceutical Co., Ltd. | Ｓ１ｐ受容体結合能を有する化合物およびその用途 |
| JP2006064757A (ja) | 2004-08-24 | 2006-03-09 | Systec Kyowa:Kk | ディスプレイ固定用スタンド |
| CA2591399C (en) * | 2004-12-13 | 2014-05-20 | Ono Pharmaceutical Co., Ltd. | Aminocarboxylic acid derivative and medicinal use thereof |
| WO2007092638A1 (en) * | 2006-02-09 | 2007-08-16 | University Of Virginia Patent Foundation | Bicyclic sphingosine 1-phosphate analogs |
| UA107360C2 (en) | 2009-08-05 | 2014-12-25 | Biogen Idec Inc | Bicyclic aryl sphingosine 1-phosphate analogs |
| CN106278999B (zh) | 2011-02-07 | 2019-10-25 | 比奥根Ma公司 | S1p调节剂 |
| EP3228615B1 (en) * | 2014-12-04 | 2021-01-20 | ONO Pharmaceutical Co., Ltd. | Dihydronaphthalene derivatives useful in the treatment of s1p5-mediated diseases |
| WO2017131149A1 (ja) | 2016-01-29 | 2017-08-03 | 小野薬品工業株式会社 | テトラヒドロナフタレン誘導体 |
| JP2018029549A (ja) * | 2016-08-26 | 2018-03-01 | キユーピー株式会社 | 苦味低減方法 |
| TWI789495B (zh) | 2018-02-22 | 2023-01-11 | 日商小野藥品工業股份有限公司 | 具有ｓ1ｐ5受體作動活性的化合物 |
| EP4019496B1 (en) * | 2019-08-20 | 2024-06-05 | ONO Pharmaceutical Co., Ltd. | Salt and crystal form of compound having agonistic activity to s1p5 receptor |
-
2019
- 2019-02-21 TW TW108105841A patent/TWI789495B/zh active
- 2019-02-21 MX MX2020008523A patent/MX2020008523A/es unknown
- 2019-02-21 FI FIEP19756600.3T patent/FI3757091T3/fi active
- 2019-02-21 US US16/970,865 patent/US11198672B2/en active Active
- 2019-02-21 DK DK19756600.3T patent/DK3757091T5/da active
- 2019-02-21 HU HUE19756600A patent/HUE068382T2/hu unknown
- 2019-02-21 PT PT197566003T patent/PT3757091T/pt unknown
- 2019-02-21 CN CN201980014718.7A patent/CN111757869B/zh active Active
- 2019-02-21 PL PL19756600.3T patent/PL3757091T3/pl unknown
- 2019-02-21 KR KR1020207023907A patent/KR102823671B1/ko active Active
- 2019-02-21 TW TW111146609A patent/TWI821061B/zh active
- 2019-02-21 JP JP2020501047A patent/JP7211410B2/ja active Active
- 2019-02-21 AU AU2019224344A patent/AU2019224344B2/en active Active
- 2019-02-21 SG SG11202007896YA patent/SG11202007896YA/en unknown
- 2019-02-21 EP EP19756600.3A patent/EP3757091B9/en active Active
- 2019-02-21 WO PCT/JP2019/006637 patent/WO2019163917A1/ja not_active Ceased
- 2019-02-21 IL IL276656A patent/IL276656B1/en unknown
- 2019-02-21 CA CA3091216A patent/CA3091216A1/en active Pending
- 2019-02-21 ES ES19756600T patent/ES2993172T3/es active Active
- 2019-02-21 MY MYPI2020004122A patent/MY210277A/en unknown
- 2019-02-21 EP EP24190856.5A patent/EP4431157A3/en active Pending
-
2020
- 2020-08-20 PH PH12020551297A patent/PH12020551297A1/en unknown
-
2021
- 2021-11-08 US US17/521,004 patent/US12049445B2/en active Active
-
2023
- 2023-01-10 JP JP2023001815A patent/JP7485103B2/ja active Active
-
2024
- 2024-06-14 US US18/744,303 patent/US20240327342A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2019000187A (es) | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo | |
| ECSP20013248A (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos | |
| JOP20230235A1 (ar) | عقاقير أولية جديدة من الكاتيكولامين للاستخدام في علاج مرض باركنسون | |
| MA39995B1 (fr) | Composés destinés à traiter l'amyotrophie spinale | |
| EA202092253A1 (ru) | Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5 | |
| PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
| PH12014500326B1 (en) | Heterocyclic derivative and pharmaceutical drug | |
| EP4442695A3 (en) | 19-homo, 3.alpha.-hydroxy-steroid-20-one compounds for treating cns disorders | |
| MX2019015371A (es) | Derivados de dihidro-pirrolo-piridina. | |
| MX2019008690A (es) | Compuestos espiro heterociclicos como inhibidores de magl. | |
| AR111693A1 (es) | Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga | |
| PH12020551297A1 (en) | Compounds having s1p5 receptor agonistic activity | |
| MX2019008626A (es) | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl). | |
| EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
| MX2021010122A (es) | Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos. | |
| EP4249071A3 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| EA201171087A1 (ru) | СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ | |
| JOP20200263B1 (ar) | مُعدِّلات تفارغية موجبة تجاه مستقبل دوبامين d1 | |
| EA202091604A1 (ru) | Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом | |
| EP4494705A3 (en) | Non-peptide oxytocin receptor agonists | |
| MX2021003508A (es) | Derivados de 5-azaindazol como antagonistas del receptor de adenosina. | |
| EA202190316A1 (ru) | Конденсированное производное лактама | |
| MX2024013291A (es) | Metodos para tratar trastornos neurodegenerativos | |
| EP4285998A3 (en) | Glycolipids and pharmaceutical compositions thereof for use in therapy | |
| MX2019014321A (es) | Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias. |